Tag: metastatic urothelial carcinoma
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Unlock global potential with Bank of Sydney’s trade finance solutions
In an increasingly globalised economy, Australian manufacturers face the dual challenge of managing complex international supply chains while seizing opportunities for global expansion. Trade finance, a crucial financial tool, can help businesses mitigate risks, improve cash flow, and facilitate cross-border trade with confidence.
